An Innovative Platform in Oral and Nasal Antibody Administration

A Novel Approach for Treatment of Hepatocellular Carcinoma

January 2020

TLSA : TILS:

DISCLAIMER AND FORWARD LOOKING STATEMENTSThe content of this presentation has been prepared for the purpose of providing general information about, and an overview of, the Company and its business. It is notintended to be a complete review of all matters concerning the Company and nor has it been independently verified . Whilst the presentation has been prepared in goodfaith and the Company has taken all reasonable care to ensure the information and facts contained in this presentation are accurate and up-to-date, it does not make anyrepresentation or warranty, express or implied, as to the accuracy or completeness of any information included in this presentation . Neither the Company nor any of itsdirectors, officers, employees or agents shall be liable for any loss arising directly or indirectly from the use of or reliance upon this presentation or in relation to theadequacy, accuracy, completeness or reasonableness of the information it contains. All and any such liability is expressly excluded to the fullest extent permitted by law.The information in this presentation is subject to updating, completion, revision, further verification and amendment without notice .This presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities including ordinary shares in theCompany nor does it constitute an invitation or inducement to engage in investment activity in relation to any securities, including the ordinary shares of the Company . Itdoes not purport to contain information that shall form the basis of or be relied upon in making such investment decisions. If you require any advice, please consult with aprofessional financial adviser. All investments are subject to risk. The value of securities may go down as well as up. Past performance cannot be relied on as a guide forfuture performance .

This presentation may contain certain forward -looking statements concerning the financial condition, results of operations and businesses of the Company . All statementsother than statements of historical fact are, or may be deemed to be, forward -looking statements . Forward -looking statements are statements of future expectations thatare based on management’s curre nt e xpe ctations and assum ptions and involve known and unknown risks and unce rtaintie s that could cause actual re sults, pe rform anceor e ve nts to d iffe r m ate rially from those e xpre sse d or im plie d in the se state m e nts. All forward-looking state m e nts containe d in this pre se ntation are e xpre ssly qualifie d inthe ir e ntire ty by the cautionary state m e nts containe d or re fe rre d to in this se ction. You should not p lace undue re liance on forward -looking state me nts. Each forward -looking state m e nt spe aks only as of the date of this pre se ntation. The Com pany doe s not unde rtake any obligation to publicly update or re vise any forward -lookingstate m e nt as a re sult of ne w inform ation, future e ve nts or othe r inform ation. In light of the se risks, re sults could d iffe r m ate rially from those state d , im plie d or infe rre d fromthe forward -looking state m e nts containe d in this pre se ntation.

In the UK, this pre se ntation has not be e n approve d by an authorise d pe rson and is be ing d istribute d on the basis that e ach pe rson in the UK to whom it is issue d isre asonably be lie ve d to be such a pe rson as is de scribe d in Artic le 19 (inve stm e nt profe ssionals) or Artic le 49 (high ne t worth com panie s, unincorporate d associations e tc .)of the Financial Se rvice s and Marke ts Act 2000 (Financial Prom otion) Orde r 2005 (SI 2005/ 1529) or are pe rsons to whom an invitation or induce me nt to e ngage ininve stme nt activity (within the m e aning of se ction 21 of the Financial Se rvice s and Marke ts Act 2000) in conne ction with the issue or sale of any se curitie s m ay othe rwiselawfully be com m unicate d or cause d to be com m unicate d . Pe rsons who do not fall within such de scrip tions m ay not act upon the inform ation containe d in thispre se ntation.

2

33

EXECUTIVE TEAM

Key Strengths of the Management Team

Successful credentials in entrepreneurship

Strong history in biotechnology deals

Proven ‘Bench to market’ record

Strong credentials in Science and Business

Co-founder , EVP & CSO of Synergy Pharmaceuticals, NASDAQ: SGYP

The pioneer of GC-C agonist technology

Inventor of TRULANCE® approved forChronic constipation and IBS -C

VP, Callisto Pharmaceuticals Group Leader, Monsanto Co.

Kunwar Shailubhai PhD, MBACEO & CSO

Previously Group Finance Director at Pharmentis –Teva Ratiopharm spin off

Executive Director at Alliance Boots, Snia, Accenture and FIAT Group

MBA, Bocconi University, Milan Corporate Finance, London Business

School. BSc Accounting and Finance

Tiziano Lazzaretti Chief Financial Officer

Gabriele CerroneExecutive Chairman

Prove n track re cord & e xpe rie nce in financing b iote chnology com panie s

Se rve d as chairm an of 2 b iote ch com panie s with m arke t cap ove r $2Bn

Inhib ite x sale $2.5Bn Syne rgy / Trovage ne / Ge nsignia /

Rasna / Contravir / Siga Te chnologie s MBA, Ste rn School of Busine ss, NY,

USA

SCIENTIFIC ADVISORY COMMITTEEHoward Weiner, MD

Professor of Neurology at Harvard Med Director and Founder of the Partners MS Center and Co -Director

of the Ann Romney Center for Neurologic Diseases Pioneered investigation of the mucosal immune system for the

treatment of autoimmune and other diseases

Napoleone Ferrara MD Inventor of Avastin® ($6.67Bn/ yr)*; 2010 Lasker Award Senior Deputy Director Basic Sciences, Moores Cancer Center,

UC San Diego Distinguished Prof of Pathology, School of Medicine, UC San

Diego

Kevin Herold, MD Professor of Immunobiology and Medicine and Deputy Director,

Yale Center for Clinical Investigation Director of the Yale Diabetes Center and Director of the TrialNet

Center at Yale Expert in autoimmune diseases and anti -CD3 monoclonal

antibody therapies

Arun Sanyal MD

Charles Caravati Distinguished Professor and Chair, Division of Gastroenterology, Hepatology and Nutrition at Virginia Commonwealth University School of Medicine

Leader in the field of liver diseases

Angelo Sangiovanni , MD Adjunct Professor of Gastroenterology at the University of Milan Leader in liver disease and gastroenterology Awarded Best Scientific Publication in clinical Hepatology in Italy

Fabio Piscaglia , MD

Associate Professor, Medical and Surgical Sciences at the University of Bologna

Leader in liver diseases and transplantation 2017 Winner of a National Institute of Health (NIH) of United

States of America grant

Erica Villa, MD

Professor and Chief GI Unit Chairman of the Department of Internal Medicine Universitaria di Modena, Policlinico , Modena, Italy Leader in Clinical Hepatology and Translational Medicine

Innovative platform technology for oral and nasal formulations can transform the administration of Monoclonal Antibodies (‘mAbs’)

Two de -risked assets in clinical evaluation that target the root causes of autoimmune/inflammatory diseases and cancer

Milciclib has received ‘Orphan Drug Designation’ in US and EU for treatment of thymic carcinoma/thymoma (TC/T)

Assets for unmet needs in a multi billion -dollar addressable market NASH - $35 billion Crohn’s Disease - $10 billion/year by 2025 Liver cancer - $1.5 billion/year by 2022

Strong intellectual property 255 patents approved and 30 pending Covers composition of matter, process and disease indications Oral formulation technology applicable to other mAbs therapeutics

Experienced and successful biotech management team

A leverageable biotechnology platform for use in additional therapeutics

INVESTMENT HIGHLIGHTS

Orphan Drug DesignationMet primary and secondary

endpoints in 2 separate Phase 2 trials in TC/T.

Phase 2a in sorafenib -resistant patients completed

Well -tolerated topline data reported July 2019

Nasal Trial: Phase 2 starting shortly.

Phase 1 trial completed

Data - August 2019

Oral Trial: FDA approved IND. Phase 1 oral trial to begin shortly

5 5

Market potential for our technologies

Foralumab Nasal administration for Neurodegenerative diseases: Recent clinical data

indicates that foralumab was safe and produced an anti - inflammatory effect. A phase 2 trial in patients with progressive multiple sclerosis will commence shortly

Oral administration for digestive diseases (Crohn’s Disease and NASH)Our IND was approved by the FDA. A phase 1 trial in healthy volunteers will be completed by 4Q 2019.

Milciclib Hepatocellular carcinoma: Clinical data from a recently completed phase 2a

in sorafenib-resistant advanced cases of HCC suggests that milciclib is outperforming the existing therapies

Cholangiocarcinoma: Milciclib has the potential to treat this orphan cancer indication for which no treatment options are available. Our IP covers this disease indication.

• HCC• Cholangiocarcinoma

Oral:• Crohn’s Disease• Celiac Disease• NASH

Nasal:• Pro-MS• Neurodegenerative• Autoimmune

BIG PHARMA INTEREST

6

platform enables…

A REVOLUTIONARY PLATFORM

Costly Infusion Center Poor patient compliance Higher toxicity Systemic treatment to affect

whole body Infusion related side effects

TODAY’S ANTIBODY ADMINISTRATION OPTIONS ARE MOSTLY I.V.

Antibodies (mAbs) reformulated for oral

administration

Antibodies (mAbs)reformulated for nasal

administration

Ease of useSuperior complianceTopical action in gut

Minimized toxicityTake home Rx

No costly infusion

PATIENT &PROVIDER BENEFITS

THE LARGE MARKET OPPORTUNITY

Marke t opportunity for m Ab the rape utics is

greater than

$86BILLION

7 7

SWITCH ANTIBODY ADMINSTRATION FROM INTRAVENOUS TO ORAL AND NASAL ROUTES

ROUTE OF ORAL OR NASAL ADMINISTRATION DEPENDS ON DISEASES

HEALTHY LIVER NON-ALCOHOLIC FATTY LIVER DISEASE NAFLD

25-30% of Population

CIRRHOSIS

Irreversible Liver Damage

HEPATOCELLULAR CANCER

Immune cells infiltration

Foralumab (Anti -CD3) for NASH and Crohn’s Disease

NASH global market ~ $35 B/year Crohn’s Disease market: $10B /year by 2025 Oral/nasal delivery is a novel, completely differentiated approach Strong IP on the ‘Revolutionary’ approach with significant market

potential

THE MULTI BILLION DOLLAR MARKET FOR LIVER DISEASES AND CROHN’S DISEASE

EXCESSIVE FAT DEPOSITS LEAD TO LIVER INFLAMMATION INFLAMMATORY AND FIBROTIC PROCESSES LEAD TO MALIGNANCY

NON-ALCOHOLIC STEATOHEPATITIS NASH

Generally Asymptomatic Reversible

3- 5% of Population

Reversible

Milciclib for Liver Cancer

HCC ($1.5B / ye ar by 2022): Me d ical ne e d to have a safe r and e ffe c tive d rug with highe r re sponde r rate s

Milc ic lib : An oral d rug with com ple te ly d iffe re ntia te d MOA with long-te rm safe ty

Supe rior safe ty p rofile

20% Over 10 Years

HBV/HCV

X

8

DISCOVERY LEADOPTIMIZATION PRE-CLINICAL IND PHASE 1 PHASE 2 PHASE 3

DEVELOPMENT PIPELINE

Intranasal formulation for Neurodegenerative diseaseNasal Administration

Enteric coated capsules * Oral Administration

Crohn’s disease I.V. Administration – Conducted by Novimmune

Thymic Carcinoma / ThymomaOrphan Drug Designation in U.S. and E.U

Milciclib + Gemcitabine in refractory solid tumorsPotential Adjuvant Treatment

HCC monotherapySorafenib Resistant Patient

HCC combination with a Tyrosine Kinase InhibitorPotentially for synergism

BEGINNING PHASE 2Nasal Trial

Pro-MS

BEGINNINGPHASE 2

Oral

Crohn’s

TWO PHASE 2 TRIALS

COMPLETED TC / T Oral

PHASE 2aCOMPLETED

HCC Oral Monotherapy

9 9*F i C h ’ Di C li Di d NASH

10

PLATFORMTECHOLOGIES

NASAL ADMINISTRATION

Phase 1 trial completed for related neurodegenerative diseases such as

Progressive Multiple Sclerosis (Pro -MS) . Phase 2 trial in Pro-MS to start shortly

ORAL ADMINISTRATION

FDA has allowed initiation of clinical studies with enteric coated capsule for

oral administration with Foralumab. Phase 1 completed December, 2019.

10

A BIOTECHNOLOGY PLATFORM ENABLING ORAL AND NASAL

ADMINISTRATION OF FORALUMAB AND OTHER MONOCLONAL ANTIBODIES

OKT3MUROMONAB

CHAGLYCD3 OTELIXIZUMAB

NUVION VISILIZUMAB

HOKT31(ALA-ALA) TEPLIZUMAB FORALUMAB

IgG2a IgG1*Agly

IgG2*AA

IgG2*AA

IgG1*AE

Fully Mouse Chimeric & Humanized

Humanized Humanized Fully Human

THE ONLY FULLY HUMAN ANTI-CD3 MAB

Approved by the FDA for solid organ transplantation immuno-suppression

11

CD3-SPECIFIC MONOCLONAL ANTIBODIES IN CLINICAL DEVELOPMENT

Oral and Nasal Administration Market Opportunities

Tiziana’s platform of oral and nasalmAbs administration potentially

enhances efficacy and reduces toxicity

Foralumab is unique: functionally equivalent to OKT3 with minimal immune reactions when administered IV

PANETH CELL

Dendritic cells

M CELL

INTESTINAL EPITHELIAL CELLS

Lymphoid follicle

Mesentericlymph node

Treg cell induction

Site-targetedImmunomodulation

Gut Lumen

INNATE IMMUNE SYSTEM

Macrophages

NKT cells

Intraepithelial lymphocytes

NOVEL APPROACH FOR SITE-TARGETED IMMUNOMODULATIONHOW DOES OUR PLATFORM TECHNOLOGY WORK?

Lamnia Propria

12

Patent covers and other mAbs

ANTI - CD3 ANTIBODY FORMULATIONSApplicant(s): Tiziana Life Sciences PLCInventor(s): SHAILUBHAI, Kunwar

US Non-Provisional Patent ApplicationNo.:62/ 380,652, filed August 29, 2016PCT Application PCT/US 2017/ 049211, filed, Aug 29, 2017

Patent estate Exclusive license for

composition of matter Composition of matter patent for oral

formulation Additional patent applications pending Oral formulation technology applicable to

other mAbs

Nasal administration of

Proof-of-concept demonstrated in animal studies

Phase 1 study for neurodegenerative diseases at Brigham and Women’s Hospital, Harvard Medical School; completed and well -tolerated up to 250 µg

Positive Top line data received August 2019, CSR in preparation

In-licensed nasal delivery technology from Brigham and Women’s Hospital, Harvard Medical School

ORAL AND NASAL FORMULATION PATENTS PENDING

13

Phase 1 Trial Conducted at Brigham and Women’s Hospital Com ple te d De ce m be r 2019

Single Asce nd ing Dose , double -b lind , p lace bo-controlle d study in he althy subje cts

Foralum ab adm iniste re d at 1.25, 2.5 and 5.0 m g/ dose as stab ilize d powde r form ulation in e nte ric-coate d capsule s

KEY FINDINGS

1. Well -tolerated at all doses tested

2. No drug -related safety issues observed

Foralumab Enteric Capsules Safety Study

14

Determined the immunologic effects and safety of orally delivered anti -CD3antibody in patie nts with m ode rate -to-se ve re ulce rative colitis (UC)

Six subje cts re ce ive d oral OKT3

* Boden, E. K., Canavan, J. B., Moran, C. J., McCann, K., Dunn, W. A., Farraye, F. A., Ananthakrishnan , A. N., Yajnik, V., Gandhi, R., Nguyen, D. D., Bhan, A. K., Weiner, H. L., Korzenik , J. R., Snapper, S. B. Immunologic alterations associated with oral delivery of anti -CD3 (OKT3) monoclonal antibodies in patients with moderate -to-severe ulcerative colitis. Crohn's & Colitis 360 (2019). 183: 240-246.

KEY FINDINGS

1. The biologic response to treatment with oral anti-CD3 were increased proliferation and anti-inflammatory gene expression profile in peripheral blood mononuclear cells

2. 3 of 6 patients had a clinical response including one patient in clinical remission

3. Treatment was well-tolerated with no serious treatment-related adverse events

FINDINGS SUPPORT TIZIANA’S ORAL PLATFORM

15

THIRD PARTY RESEARCHERS IN PEER-REVIEWED, CROHN’S & COLITIS 360*

OKT3, a murine mAb, was withdrawn from the market due to severe side effects Foralumab is a fully human anti-CD3 mAb with minimal side effects

PROOF-OF-CONCEPT IN NASH PATIENTS

STUDY DESIGN SAFETY IMMUNOLOGICAL EFFICACY BIOMARKERS

36 subjects with NASH and type II diabetes

Randomized, single-blinded, placebo-controlled

9 per group, not powered for statistical significance

0.2, 1.0, 5.0 mg or placebo daily for 30 days

Primary endpoints: safety and trends in immunomodulation

Secondary endpoint: indication or trend of efficacy through biomarkers

Follow up: Days 0, 14, 30, 60

Hadassah Medical Center, Jerusalem Israel

Well tolerated by all patients in all groups

No systemic drug-related adverse events

No changes in vital signs, serum biochemistry and hematological parameters during treatment or follow-up periods (30-days post-treatment)

No changes in lymphocyte and CD+ cell counts

No changes in weight or BMI or HbA1C lipid GLP-1, or CRP levels in any of the groups

Increases in Treg markers consistent with induction of Tregs

Anti-inflammatory markers ↑

CD4+CD25+LAP+ Treg cells, TGFβ↑

Positive trends, some of which were statistically significant

AST ↓ – liver enzyme indicating reduced liver inflammation

Glucose ↓ – favorable for subjects with type-2 diabetes

Insulin ↓ – favorable for subjects with type-2 diabetes

16

ORAL TREATMENT WITH MURINE ANTI-CD3 (OKT3) EFFECTIVE IN A PHASE 2 TRIAL WITH NASH1

Sources: 1) Lalazar, G., Mizrahi, M., Turgeman , I., Adar, T., Ya’Acov, A. B., Shabat, Y., . . . Ilan, Y. (2015). Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T -cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo -Controlled Trial. Journal of Clinical Immunology, 35(4), 399 -407.

17

KEY FINDINGS

1. Foralumab is as potent as OKT3

2. Treatment is effective in humanized mice studies

3. Mechanism of action is via activation of Tregs that systemically circulate to elicit targeted immunomodulation

FORALUMAB IS FUNCTIONALLY EQUIVALENT TO OKT3Oral Treatment prevents skin xenograft rejection in mice with human immune systemsMineko Ogura, Songyan Deng, Paula Preston-Hurlburt, Hideki Ogura, Kunwar Shailubhai, Chantal Kuhn, Howard L Weiner, and Kevan C. Herold

Clinical Immunol, 2017. 183: 240-246

18

Anti -CD3 Monoclonal Antibodies Induce Regulatory T Cell (T reg) for the Treatment of Autoimmune and Inflammatory Diseases

Potential for treatment of Type 1 diabetes is well established

Preservation/protection of β-ce lls is de m onstrate d in p re -c linical stud ie s

Im prove d insulin re sistance and g lucose tole rance in Type 2 d iabe te s by induction of T re gs

Anti-CD3’s show pote ntial in p re ve nting g raft ve rsus host d ise ase (GvHD) in he m atopoie tic ste m ce ll transp lantation (HSCT) via induction of T re gs Patie nts with re nal allograft re je ction dose d IV with foralum ab , de laye d g raft

re je ction and im prove d re nal function Foralumab shows promise for successful stem cell/CAR -T transplantation

Anti-CD3 mediates immune tolerance by induction of T regs

mediated by IL -10 (nasal tolerance) and TGF-β and LAP complex leading to differentiation of T cells to T regs (oral tolerance)

LFA-1 (cell adhesion molecule critical for T reg homeostasis and function)

Induces apoptosis of effector T cells to normalize balance of Treg:Teff cells ratio

Anti-CD3 antibody increases T reg:Teff ratio

19

KEY FINDINGS

1. Teplizumab (humanized OKT3), administered intravenously,significantly slowed progression to clinical Type 1 diabetes, with a median delay in the diagnosis of diabetes of 2 years

2. At the end of the trial, 57% of subjects treated with Teplizumab showed slowed progression to development of Type 1 diabetes, while 72% of the placebo-treated subjects progressed to clinical diabetes

POTENTIAL TO TREAT TYPE I DIABETES

New England Journal of Medicine* provides clinical evidence for the potential use of a humanized anti -CD3mAb for treatment of type 1 diabetes

*K. Herold, B. Bundy, S.A. Long, J. Bluestone, L. Dimeglio , M. Dufort , S. Gitelman, P. Gottlieb, J. Krischer, P. Linsley, J. Marks, W. Moore, A. Moran, H. Rodriguez, W. Russell, D. Schatz, J. Skyler, E. Tsalikian, D. Wherrett , A-G. Ziegler and C. Greenbaum. “ An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes,”. epub . NEJM.org June 9 2019

20

A PAN-CDK INHIBITOR FOR TREATMENT OF HEPATOCELLULAR CARCINOMA AND SOLID TUMORS

Source: Petrick et.al. J. Clin. Onc 34 (15) (2016) pg 1787-1795

Incidence of HCC is steadily increasing in males and females and subpopulations in US

20

21

SMALL MOLECULE PAN-CDK INHIBITOR

Orally -bioavailable small molecule with potent anti-tumor activity in a wide range of animal models

Inhibitor of kinases associated with cancer cell growth including CDK1, CDK2, CDK4 CDK5, CDK7and src-family kinases

Inhibits signaling pathways for hepato -carcinogenesis

Well tolerated in 316 patients

Improved toxicity profile over the current standard of care anticipated

A drug with completely differentiated MOA and long-term safety

22

CLINICAL DATA FROM MILCICLIBTrial design : Oral administration (100 mg/day, consecutive 4 days a week in a 4 -week cycle). Total patients 30 to be enrolled. Duration 6 months

Primary end point: safety Secondary end points: PFS, ORR & TTPExploratory: AFP and miRNA profiling

Compassionate use : Upon request of patients with EC approval

Trial complete: Data from 28 out of 31 evaluable sorafenib -resistant HCC patients 14 patie nts com ple te d tre atm e nt as pe r p rotocol Nine approve d for com passionate use . Se ve n patie nts com ple te d

9, 9, 10 , 11, 13, 13 and 16 m onths , re spe ctive ly. No drug related deaths in the trial Tre atm e nt was we ll- tole ra te d Adve rse e ve nts we re m anage ab le Time to progression 5.9 months out of 6 months duration of trial Stabilized Disease (SD) 61% Clinical Benefit Response 64%

PHASE 2A TRIAL IN SORAFENIB-RESISTANT HCC PATIENTS

Two p a t ie nts cu rre nt ly cont inu ing com p a ss iona te use t re a tm e nt for 15 m onths

23

THYMIC CARCINOMA AND THYMOMA UPDATES Two Phase 2 trials with Milciclib in US, Italy and France

o Trial 006: Thym ic carc inom a and Thym om a m ixe d population (72 patie nts)o Trial 007: Thym ic carc inom a and Thym om a m ixe d population (30 patie nts)

Rare cance rs with ve ry fe w case s: Orphan Dise ase Ind ications

Positive c linical data

Primary endpoint (progression free survival) and secondary endpoint (overall survival) met in both trials separately

Thym ic carc inom a is an aggre ssive m e tastatic cance r and it has no approve d the rapy

Milcic lib as a s ing le age nt m e t p rim ary as we ll as se condary e ndpoints in thym ic carc inom a in both trials

Under compassionate use, few patients continued the treatment for over five years

Se e king guidance from FDA/ EMA re gard ing cond itional m arke ting approval

24

MILCICLIB OVERCOMES DRUG RESISTANCE

KEY FINDINGS

1. Milciclib well-tolerated with manageable side effects in patients with refractory solid tumors

2. Oral treatment in combination with gemcitabine demonstrated clinical activity in patients who were non-responder to existing chemotherapeutic drugs

3. Recommended Phase 2 dose (RPD) found to be 80mg/m2/day for milciclib and 1000mg/m2/day for Gemcitabine

4. Overall response rate was 36%

5. Results suggest further evaluation in other solid cancers either as monotherapy or combo-therapy

PATIENTS RAPIDLY ACQUIRE RESISTANCE TOWARDS CHEMOTHERAPIES

Phase 1 Dose-Escalation Study of Milciclib in Combination with Gemcitabine in Patients with

Refractory Solid Tumors*

Swimmerplot showing treatment duration. Tumor type was indicated for patients having a prolonged stable disease or a partial response. M Milciclib; G gemcitabine.

* Cancer Chemotherapy and Pharmacology, June 2017, 79(6), 1257-1265

INTELLECTUAL PROPERTY PORTFOLIO

25

FAMILY SUBJECT PRIORITY STATUS EXPIRES JURISDICTION

TZLS-401

Methods of Use (Autoimmune or Inflammatory diseases and disorders) 2004 Issued 2025

Australia, Canada, China, Hong Kong, Israel, Japan, Mexico, Norway, Singapore, South Africa, Ukraine, Armenia, Austria, Azerbaijan, Belgium, Belarus, Switzerland, Germany, Denmark, Spain, France, United Kingdom, Ireland, Italy, Kyrgyzstan, Kazakhstan, Luxembourg, Moldova, Netherlands, Portugal, Russian Federation, Sweden, Tajikistan, Turkmenistan,

Composition and methods of use 2004 Issued/ Pending 2025

US, Armenia, Australia, Austria, Azerbaijan, Belarus, Canada, China, Denmark, France, Germany, Hong Kong, India, Israel, Italy, Japan, Kazakhstan, Kyrgyzstan, Mexico, Moldova, Netherlands, Norway, Republic of Korea, Russian Federation, Singapore, South Africa, Spain, Switzerland, Tajikistan, Turkmenistan, and Ukraine Pending: Brazil, Japan (divisional), Singapore (divisional), US (divisional)

Methods of Use (In combination with anti-IL-6/IL-6R antibodies) 2011 Pending 2032 US

Formulations and dosing regimen 2016 Pending 2037 US, Australia, Canada, China, Europe, Israel, Japan

Methods of Use (CNS disorders) 2017 Pending 2038 PCTMethods of Use

(gastrointestinal/autoimmune/inflammatory) 2018 Pending 2039 Provisional

T

TZLS-201

Composition of matter, methods of use, process of manufacturing 2003 Issued/

Pending 2024

US, Europe, Eurasia, Africa, Algeria, Antigua & Barbuda, Argentina, Australia, Barbados, Bosnia & Herzegovina, Brazil, Canada, Colombia, Costa Rica, Croatia, Cuba, Ecuador, Egypt, Georgia, Iceland, India, Indonesia, Israel, Japan, Korea, Kosovo, Malaysia, Mexico, Mongolia, Montenegro, New Zealand, Nicaragua, Norway, Pakistan, Philippines, Serbia, Singapore, South Africa, Sri Lanka, Taiwan, Thailand, Trinidad & Tobago, Tunisia, Ukraine, Uzbekistan, Venezuela, VietnamPending: Several in US and other countries

Methods of use (multiple indications) 2008; 2009 Issued 2029; 2030 US, EU, China, Hong Kong, JapanMethods of use (combination

therapies with cytotoxics) 2008; 2009 Issued 2029; 2030 US, EU, China, Hong Kong, JapanCompositions of related entities, formulations

and methods of treatment 2009 Issued 2030 US, EU, China, Hong Kong, JapanMethods of use (combination therapies

with therapeutic antibodies) 2006 Issued 2027 US, EU, China, Japan

Formulations of Milciclib and therapeutic combinations of the same for use in the

treatment of cancer2017 Pending 2038 US, PCT

Anti IL-6/IL-6R Antibody TZLS-501

Composition of Matter and Methods of use 2009 Issued/

Pending 2029US, Austria, Australia, Belgium, Canada, China, Denmark, France, Germany, Ireland, Italy, Japan Luxembourg, Mexico, Netherland, Spain, Sweden, Switzerland and UK . Pending: US (divisional), Japan (divisional), India

CATALYSTS GRO

WTH

OB

JECTIVESPRODUCT ACTION/OBJECTIVE DATE

Reported Phase 1 Nasal Dosing in Healthy Volunteers (Safety, Tolerability and Biomarkers of Immunomodulation)

2H 2019

Com ple te d Phase 1 Oral Tria l of Foralum ab in He althy Volunte e rs 2H 2019

Re porte d Top Line Safe ty, Efficacy and Exp loratory End Point Data from Phase 2a Monothe rapy Tria l

2H 2019

Initia te Phase 2b Live r Cance r Study of Milc ic lib in Com bination with a TKI

1H 2020

Re porte d Phase 1 Oral Dosing of Foralum ab in He althy Volunte e rs (Safe ty, Tole rab ility and Biom arke rs of Anti- inflam m ation)

1H 2020

Initia te Phase 2 in Crohn’s d ise ase and NASH with Oral Foralum ab 2H 2020

26

CAPITAL STRUCTURE

Ordinary Issued Shares 136,654,516Warrants 5,086,561Options 17,134,403Convertible Loan Notes 3,512,671Fully Diluted Shares 162, 388,151

27

ADS EQUIVALENT*

Ordinary Issued Shares 27,330,903Warrants 1,017,312Options 3,426,881Convertible Loan Notes 702,534Fully Diluted Shares 32,477,630

*Information prepared as of January 10, 2020. 1 ADS represents 5 ordinary shares.The company is contemplating/planning to migrate to Bermuda in the second quarter which will enable it to de-list from AIM, eliminate its ADR program and have

Bermuda common shares instead listed on Nasdaq.

An Innova tive Pla tform in Ora l and Nasa l Antib od y Ad m inis tra tion

A Dis tinc t Ap p roach for Tre a tm e nt of He p a toce llu la r Carc inom a

CONTACT USUS Headquarters

Tiziana Life Sciences Inc420 Lexington Avenue Suite 2525

New York, NY 10170

Research and Development CenterTiziana Life Sciences Inc

Pennsylvania Biotechnology Center of Bucks County3805 Old Easton RD

Doylestown, PA 18902 -8400

UK HeadquartersTiziana Life Sciences plc

55 Park LaneLondon W1K 1NAUnited Kingdom

+ 1 (267) 982 9785mpreiss@tizianalifesciences.com

www.tizianalifewsciences.comTLSA: TILS: